Interactive Features

Quiz

Enfortumab Vedotin for Patients With Advanced Urothelial Carcinoma

10/19/2023

True or False: According to findings from the phase 3 EV-301 trial, enfortumab vedotin maintained clinically meaningful overall survival benefit at a median follow-up of approximately 2 years, compared with chemotherapy, among patients with...

True or False: According to...

10/19/2023

Oncology

Quiz

NECTIN-4 Expression During Metastatic Spread in Urothelial Carcinoma

02/10/2023

In a study evaluating the changes in membranous NECTIN-4 protein expression among urothelial carcinoma progression, what percentage of cases demonstrated a decrease of NECTIN-4 expression during metastatic spread?

In a study evaluating the...

02/10/2023

Oncology

Quiz

Quiz: Rogaratinib Compared With Standard Chemotherapy for FGFR-Altered Urothelial Carcinoma

12/01/2022

In the open-label, multicenter FORT-1 trial, how did the pan-FGFR inhibitor rogaratinib compare to standard chemotherapy, in terms of efficacy in treating patients with FGFR-altered urothelial carcinoma?

In the open-label, multicenter...

12/01/2022

Oncology

Quiz

Quiz: Following TURBT, which treatment was found to be a safe, effective alternative to BCG for patients with NMIBC?

10/18/2022

Following transurethral resection of bladder tumor, which treatment was found to be an effective and safe alternative to bacillus Calmete-Guérin for patients with non-muscle invasive bladder cancer?

Following transurethral...

10/18/2022

Oncology

Quiz

Quiz: Radical Cystectomy vs Intravesical Therapy for Non-Muscle Invasive Bladder Cancer

09/02/2022

What was the difference in survival found between patients with non-muscle invasive bladder cancer who underwent radical cystectomy vs those who underwent intravesical therapy, within 12 months of receiving BCG?

What was the difference in...

09/02/2022

Oncology

Test Your Knowledge

Quiz: Which Phase 2 Trial Led to the Approval of Sacituzumab Govitecan for aUC?

02/20/2022

The approval of sacituzumab govitecan for patients with advanced urothelial cancer was based on which phase 2 trial?

The approval of sacituzumab...

02/20/2022

Oncology

Test Your Knowledge

Quiz: Which Phase 2 Trial Led to the Approval of Sacituzumab Govitecan for aUC?

02/20/2022

The approval of sacituzumab govitecan for patients with advanced urothelial cancer was based on which phase 2 trial?

The approval of sacituzumab...

02/20/2022

Oncology

Quiz

Quiz: Which Immunotherapy Drug Treats Advanced or Metastatic Urothelial Cancer?

07/01/2021

Which immunotherapy drug was recently granted accelerated approval by the FDA to treat adult patients with locally advanced or metastatic urothelial cancer?

Which immunotherapy drug was...

07/01/2021

Oncology

Quiz

Quiz: Does Nivolumab Provide the Longest DFS Rate for Urothelial Carcinoma?

07/01/2021

In a recent trial that evaluated various treatments for patients with high-risk muscle-invasive urothelial carcinoma, adjuvant nivolumab provided the longest disease-free survival rate.

In a recent trial that evaluated...

07/01/2021

Oncology

Test Your Knowledge

Quiz: Risk of Recurrence and Progression for Patients with NMIBC

02/19/2021

In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?

In patients with NMIBC, does...

02/19/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology